Navigation Links
N30 Pharma Announces Completion of Phase 1 Clinical Studies With N30-201
Date:5/5/2008

BOULDER, Colo., May 5 /PRNewswire/ -- N30 Pharma (N30), a biopharmaceutical company focused on the discovery, development, and commercialization of drugs that target endogenous s-nitrosothiols, announced today that it has successfully completed Phase I study of N30-201 in patients with mild to moderate asthma, as well as healthy volunteers. N30 intends to develop N30-201 for the treatment of reactive and obstructive airway diseases, including Cystic Fibrosis and asthma.

"We are pleased to have completed the Phase 1 set of human studies of N30-201. We believe that N30-201 could be an important therapy for the treatment of many respiratory diseases. Determining the safety of acute administration of N30-201 to asthmatic, as well as healthy human subjects, is an important step." commented Charles Scoggin, M.D., Chairman of N30 Pharma.

The primary endpoint of the study is patient safety and characterization of adverse events, but the company collected pharmacokinetic and pharmacodynamic data of ascending doses of N30-201, including effects on the airway.

About N30-201

N30-201 is a proprietary nebulized formulation of s-nitrosoglutathione (GSNO), an endogenous bronchodilatory molecule that serves as a critical store of nitric oxide (NO) bioactivity in the human airway.

About N30 Pharma

N30 Pharma is developing s-nitrosothiol therapies for critical unmet needs in important respiratory and cardiovascular diseases. S-nitrosothiols are endogenous molecules which store and transduce nitric oxide, and are critical modulators of airway and vascular smooth muscle tone. N30's drug development strategy focuses on administration of GSNO to the human airway, and the development of inhibitors of GSNO reductase. GSNO reductase is the key enzyme in the body that breaks down GSNO. These approaches allow N30 to deliver targeted, long lasting, physiologically relevant doses of s-nitrosothiols to target systems. N30 is a privately held company headquartered in Boulder, Colorado.


'/>"/>
SOURCE N30 Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
2. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
3. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
4. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
5. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
6. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
7. ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
10. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
11. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... quarter and year-end 2015 results after the Nasdaq market ... host a live conference call and webcast to discuss ... afternoon, February 11, 2016 at 4:30 p.m. Eastern Time ... --> http://www.neurocrine.com . --> Participants can ...
(Date:2/8/2016)... DUBLIN , Feb. 8, 2016 ... addition of the "Global Skin Protective Equipment ... --> http://www.researchandmarkets.com/research/fqx6nz/global_skin ) has announced ... Equipment Market 2016-2020" report to their offering. ... ( http://www.researchandmarkets.com/research/fqx6nz/global_skin ) has announced the addition of ...
(Date:2/8/2016)... Intarcia Therapeutics, Inc. today announced the appointment of ... created role of Vice President, Head of Global Medical ... of leadership experience at leading pharmaceutical, biotechnology, and health ... Most recently Dr. Yee served as VP, Head of ... Officer at AstraZeneca, where he led medical affairs across ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... , ... Discover the Rocky Mountain region’s longest running and impressive garden and ... also get to see the most incredible gardens and home improvement experts that attend ... Colorado Convention Center - 700 14th St. Denver CO, is an exciting event that ...
(Date:2/8/2016)... Nevada (PRWEB) , ... February 08, 2016 , ... ... RowdMap, Inc., will be speaking on how healthcare companies can use newly released ... manage the health of a population and intervene and capture the value they ...
(Date:2/7/2016)... , ... February 07, 2016 , ... ... with the latest techniques and the most minimally invasive approaches. , Women who ... particularly after menopause. Other risk factors include surgery to the pelvic floor, connective ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This ... an estimated 5000 perioperative nurses in attendance to study the latest evidence-based ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research has shown ... to reduce the frequency and level of relapse. , At the ... and Purpose,” will explore the critical tasks of the recovery phase and beyond ...
Breaking Medicine News(10 mins):